New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient.
The new-generation acetylcholinesterase inhibitor, donepezil, is useful in the treatment of mild-to-moderate Alzheimer's disease. A 72-year-old male chronic hemodialysis patient was diagnosed as having moderate Alzheimer's disease. We administered donepezil at 3 mg/day orally to the patient. After 1 month's treatment, the patient improved to a controllable psychiatric condition and was discharged from the hospital. The 24-hour plasma concentration profile of donepezil following the 3-mg once-daily dose varied from 11.1 to 18.2 ng/ml. The through level of donepezil was reduced from 12.4 to 10.9 ng/ml over a 3-month period. We did not experience any episodes of drug toxicity or adverse effects in this chronic dialysis patient. Donepezil treatment might have a beneficial impact on patients with severe renal dysfunction.
Suwata
Junji
J
Department of Surgery, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan. jsuwata@saitama-med.ac.jp
Kamata
Kohzoh
K
Nishijima
Tatsushige
T
Yoshikawa
Tetsuo
T
Sano
Motoki
M
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D010880:Piperidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil